tiprankstipranks
Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR (BR:TAKP34)
:TAKP34
Brazil Market
TAKP34
Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR
RESEARCH TOOLSreports

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR (TAKP34) Price & Analysis

― Followers

TAKP34 Stock Chart & Stats

R$92.25
R$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeR$10.00 - R$100.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
R$302.90B
Enterprise ValueR$274.78K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Oct 29, 2026
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,602,106,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A

Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR News

Novavax’s partners approved for Nuvaxovid formulation for vaccination season
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
Novavax’s (NVAX) partners have received approvals for the Nuvaxovid formulation to target the SARS-CoV-2 XFG variant for the...
4h ago
SNY
TAK
Takeda announces Japan MHLW approval for Orzeyful
Takeda announces Japan MHLW approval for Orzeyful
Takeda (TAK) announced that the Japanese Ministry of Health, Labour and Welfare, or MHLW, approved the use of...
4d ago
TAK
Takeda award from Veterans Affairs posted to SAM.gov site
Takeda award from Veterans Affairs posted to SAM.gov site
A contract award dated August 7 from Department of Veterans Affairs to Takeda (TAK) Pharmaceuticals America was posted...
18d ago
TAK
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1
Takeda (TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL, an oral orexin receptor 2...
23d ago
TAK
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults
The U.S. Food and Drug Administration approved Orzeyful tablets for the treatment of narcolepsy type 1 in adults....
23d ago
TAK
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
Keros Therapeutics (KROS) announced that it will receive a $20M development milestone payment under the terms of the...
29d ago
TAK
KROS
Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
Analyst Koichi Mamegano of Bank of America Securities reiterated a Buy rating on Takeda Pharmaceutical Co, boosting the...
15d ago
TAK
Mamegano Reiterates Buy on Takeda as Q1 Beat and Pipeline Progress Support Unchanged Price Objective
Mamegano Reiterates Buy on Takeda as Q1 Beat and Pipeline Progress Support Unchanged Price Objective
Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co. The...
29d ago
TAK

TAKP34 FAQ

What was Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s price range in the past 12 months?
Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR lowest stock price was R$10.00 and its highest was R$100.00 in the past 12 months.
    What is Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s market cap?
    Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s market cap is R$302.90B.
      When is Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s upcoming earnings report date?
      Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.
        How were Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s earnings last quarter?
        Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR released its earnings results on Jul 30, 2026. The company reported R$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by R$0.002.
          Is Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR overvalued?
          According to Wall Street analysts Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR pay dividends?
            Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR does not currently pay dividends.
            What is Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s EPS estimate?
            Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR have?
            Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR has 1,602,106,800 shares outstanding.
              What happened to Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR’s price movement after its last earnings report?
              Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR reported an EPS of R$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.305%.
                Which hedge fund is a major shareholder of Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR?
                Currently, no hedge funds are holding shares in BR:TAKP34
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR (TAKP34) Earnings & Revenues

                  Historic Earnings Reports
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  A1LN34
                  Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh
                  ―
                  ―
                  A1RG34
                  arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR
                  ―
                  ―
                  B1ME34
                  BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR
                  ―
                  ―
                  REGN34
                  Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh
                  ―
                  ―
                  T1EV34
                  Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR
                  ―
                  ―
                  Compare BR:TAKP34 Stocks >
                  Popular Stocks